Delpor Advances Pipeline to Include Spasticity Maintenance Therapy with $2.5 Million NIH Grant for Tizanidine Implant

Company expects to enter clinic by 2023 and if approved, Delpor’s tizanidine implant will be the first minimally invasive, long-acting therapy for the maintenance of moderate to severe spasticity Expanded pipeline supports long-term growth in [...]

By |2021-11-16T19:19:14+00:00November 16th, 2021|News|0 Comments

Delpor Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Once-Yearly Risperidone Implant

If approved, Delpor’s risperidone implant will be the first once-yearly schizophrenia maintenance therapy. BRISBANE, CA, April 22, 2021 — Delpor, Inc. (Delpor), a clinical-stage biopharmaceutical company that utilizes innovative technologies in order to develop once-yearly [...]

By |2021-11-16T19:17:52+00:00April 22nd, 2021|News|0 Comments

Delpor to Tackle Opioid Use Disorder with $5.7 million NIH HEAL Grant Award for the Development of a Once-Yearly Naltrexone Therapy to Prevent Relapses

Company to expand the use of its PROZOR implant technology by building on the success with its lead antipsychotic program Upon successful completion of the grant’s initial phase, Delpor may receive additional funding in order [...]

By |2019-10-09T23:02:32+00:00October 9th, 2019|News|0 Comments

Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device

Delpor has exclusive rights to the patented technology and has several product candidates in development, including 3-6 month formulations of exenatide, liraglutide, and basal insulin. SAN FRANCISCO, CA, April 23, 2015 – Delpor, Inc. (Delpor), [...]

By |2018-01-02T19:57:24+00:00April 23rd, 2015|News|0 Comments
Go to Top